



## Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians



Chee Wai Wong<sup>a, b, c</sup>, Yasuo Yanagi<sup>a, b, c</sup>, Won-Ki Lee<sup>d</sup>, Yuichiro Ogura<sup>e</sup>, Ian Yeo<sup>a, b, c</sup>,  
Tien Yin Wong<sup>a, b, c, \*</sup>, Chui Ming Gemmy Cheung<sup>a, b, c</sup>

<sup>a</sup> Singapore National Eye Centre, Singapore

<sup>b</sup> Singapore Eye Research Institute, Singapore

<sup>c</sup> Duke-NUS Medical School, National University of Singapore, Singapore

<sup>d</sup> Department of Ophthalmology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea

<sup>e</sup> Department of Ophthalmology, Nagoya City University, Nagoya, Japan

### ARTICLE INFO

#### Article history:

Received 7 February 2016

Received in revised form

31 March 2016

Accepted 11 April 2016

Available online 14 April 2016

#### Keywords:

Asian age-related macular degeneration

Polypoidal choroidal vasculopathy

Choroidal neovascularization

Photodynamic therapy

Laser photocoagulation

Anti-vascular endothelial growth factor

### ABSTRACT

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in elderly people globally. It is estimated that there will be more Asians with AMD than the rest of the world combined by 2050. In Asian populations, polypoidal choroidal vasculopathy (PCV) is a common subtype of exudative AMD, while choroidal neovascularization secondary to AMD (CNV-AMD) is the typical subtype in Western populations. The two subtypes share many common clinical features and risk factors, but also have different epidemiological and clinical characteristics, natural history and treatment outcomes that point to distinct pathophysiological processes. Recent research in the fields of genetics, proteomics and imaging has provided further clarification of differences between PCV and CNV-AMD. Importantly, these differences have manifested as disparity in response to intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) treatment between PCV and CNV-AMD, emphasizing the need for accurate diagnosis of PCV and in distinguishing PCV from CNV-AMD, particularly in Asian patients. Current clinical trials of intravitreal anti-VEGF therapy and photodynamic therapy will provide clearer perspectives of evidence-based management of PCV and may lead to paradigm shifts in therapeutic strategies away from those currently employed in the treatment of CNV-AMD. Further research is needed to clarify the relative contribution of specific pathways in inflammation, complement activation, extracellular matrix dysregulation, lipid metabolism and angiogenesis to the pathogenesis of PCV. Findings from this research, together with improved diagnostic technology and new therapeutics, will facilitate more optimal management of Asian AMD.

© 2016 Elsevier Ltd. All rights reserved.

### Contents

1. Introduction .....	108
2. Epidemiology .....	109
2.1. Epidemiology of Asian AMD .....	109
2.2. Epidemiology of PCV .....	109
3. Risk factors .....	109
3.1. Risk factors for Asian AMD .....	109
3.2. Risk factors for PCV .....	110
3.3. Biomarkers for PCV and CNV-AMD .....	111
3.3.1. Systemic biomarkers .....	112
3.3.2. Aqueous/vitreous biomarkers .....	112

\* Corresponding author. Singapore National Eye Center, 11 Third Hospital Avenue, 16851, Singapore.

E-mail address: [wong.tien.yin@s nec.com.sg](mailto:wong.tien.yin@s nec.com.sg) (T.Y. Wong).

3.3.3.	Ocular risk factors	113
3.3.4.	Relationship between central serous chorioretinopathy (CSCR) and PCV	113
3.3.5.	Relationship between PCV and other retinal diseases	113
3.4.	Genetics	113
3.4.1.	Genetics of Asian AMD	113
3.4.2.	Genetics of PCV	113
4.	Clinical manifestations	114
4.1.	Clinical features and natural history of Asian AMD	114
4.2.	Clinical features and natural history of PCV	115
4.3.	Histology of Asian AMD and PCV	116
5.	Imaging- diagnosis, prognosis and response to treatment	117
5.1.	Multi-modal imaging	117
5.2.	Fluorescein and indocyanine green angiography	117
5.3.	Optical coherence tomography	119
5.3.1.	B-scan images	119
5.3.2.	En face images	121
5.3.3.	3OCT-angiography	122
5.3.4.	Fundus autofluorescence	122
5.3.5.	Retro-mode imaging	122
5.3.6.	Imaging features predictive of prognosis and response to treatment	122
6.	Classification	122
6.1.	Classification of Asian AMD	122
6.2.	Classification of PCV	123
7.	Treatment	124
7.1.	Anti-vascular endothelial growth factor	124
7.1.1.	Anti-vascular endothelial growth factor for Asian AMD	124
7.1.2.	Anti-vascular endothelial growth factor for PCV	125
7.2.	Photodynamic therapy	126
7.2.1.	Photodynamic therapy for Asian AMD	126
7.2.2.	Photodynamic therapy for PCV	126
7.3.	Combination therapy	127
7.3.1.	Combination therapy for Asian AMD	127
7.3.2.	Combination therapy for PCV (Fig. 4)	127
7.3.3.	Laser photocoagulation of PCV	128
7.3.4.	Treatment in recurrent PCV	128
7.3.5.	Treatment in peripapillary PCV	128
7.4.	Other treatments	128
7.4.1.	Radiation therapy for PCV	128
7.4.2.	Management of submacular hemorrhage in PCV	129
8.	Functional evaluation in patients with AMD	129
9.	New insights on pathogenesis from genetics and basic science research	131
10.	Current challenges and direction of future research	131
	Acknowledgements	132
	References	132

## 1. Introduction

Age-related macular degeneration (AMD) is a condition that primarily affects people over the age of 50, and is the leading cause of irreversible blindness in elderly people in the world (Lim et al., 2012b). AMD is manifested in two principle forms: early AMD (characterized by drusen and retinal pigment epithelial disturbance) and late AMD, which is further differentiated into exudative AMD (“wet” AMD) and geographic atrophy (GA) (late “dry” AMD).

There is increasing data and understanding of the epidemiology of AMD in Asians. The prevalence of early and late AMD among Asian populations aged 40 to 79 is estimated at 6.8% (Kawasaki et al., 2010). Importantly, the number of people affected is expected to increase dramatically during the coming decades with aging Asian populations; based on United Nation projections, nearly a quarter of Asians will be aged 60 years or older by 2050. Thus, it is estimated that there will be more Asians with AMD than the rest of the world combined by 2050 (Wong et al., 2014b).

Polypoidal choroidal vasculopathy (PCV) is a vascular disease of the choroid first described in the 1990s and thought to be part of the

spectrum of manifestation of AMD (Yannuzzi et al., 1990). In Asian populations, there are increasing data to show PCV is a common subtype of exudative AMD, in contrast to occult choroidal neovascularization secondary to AMD (CNV-AMD), which is the predominant form in Western populations (Lim et al., 2013; Lim et al., 2013). While the two subtypes share many common clinical features and risk factors (Laude et al., 2010), they also have different epidemiological and clinical characteristics, natural history and treatment outcomes that point to distinct pathophysiological processes. Recent research in the fields of genetics, proteomics and imaging suggest that PCV may not be as closely related to the CNV-AMD as previously thought (Ma et al., 2015; Miyake et al., 2015; Sakurada et al., 2010; Sasaki et al., 2012; Tong et al., 2006; Warrow et al., 2013). Importantly, these differences have manifested as a disparity in response to anti-vascular endothelial growth factor (anti-VEGF) treatment between PCV and CNV-AMD, emphasizing the need for accurate diagnosis of PCV and in distinguishing PCV from CNV-AMD in the approach and management of patients with exudative AMD, particular in Asians. Current ongoing clinical trials of PCV will provide clearer perspectives of

Download English Version:

<https://daneshyari.com/en/article/4031892>

Download Persian Version:

<https://daneshyari.com/article/4031892>

[Daneshyari.com](https://daneshyari.com)